Status
Conditions
Treatments
About
A multicentre trial on clinical effects of radiosurgical ablation of ventricular tachycardia (VT).
Full description
Patients with previously failed conventional RF catheter ablation will be randomized to radiosurgery (active treatment group) or repeated catheter ablation (control treatment group). Details on inclusion and exclusion criteria are provided below.
Randomization Eligible patients will be assigned to 2 treatment arms - radiosurgery (active arm) or repeated catheter ablation (control arm) in 1:1 fashion by covariate-adaptive randomization algorithm considering age, gender, etiology of structural heart disease (SHD), left ventricular (LV) ejection fraction, and serum B-type natriuretic peptide (NT-proBNP) level.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients with structural heart disease (SHD) of any etiology (ischemic, non-ischemic, congenital corrected or uncorrected)
Implanted implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D)
Prior ≥1 catheter ablation procedure for VT due to SHD of them the last one performed in the expert center and employed:
3.1 all meaningful mapping/ablation approaches (endocardial/epicardial access to left / right ventricular substrate as possible or appropriate) 3.2 precise electroanatomical mapping of the arrhythmogenic substrate in anticipation of future radiosurgery 3.3 additional mapping of structures used for precise image integration (aortic arch, left main ostium, right ventricular endocardial surface)
VT recurrence after the last catheter ablation fulfilling all criteria as follows:
4.1 clinically relevant and requiring further intervention 4.2 compatible with the previously characterized arrhythmogenic substrate 4.3 occurred on stable antiarrhythmic medication (mostly amiodarone) unless contraindicated 4.4 reversible cause excluded
Signed an Institutional Review Board (IRB)-approved written informed consent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
22 participants in 2 patient groups
Loading...
Central trial contact
Jiří Hynčica; Petr Vávra, Ass.Prof.,MD,PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal